Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

September 21, 2025 updated by: Jason Ahee, M.D.

Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery

Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent endophthalmitis

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo after cataract surgery. They will be followed for one month to determine if there is a statistically significant difference in the incidence of endophthalmitis.

Study Type

Interventional

Enrollment (Estimated)

60000

Phase

  • Phase 2
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Utah
      • St. George, Utah, United States, 84790
        • Zion Eye Institute
        • Contact:
          • Jason Ahee, M.D.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

40 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • visually significant cataracts

Exclusion Criteria:

  • allergy to fluoroquinolones, cobalamin (B12)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Treatment group
Intracameral injection of moxifloxacin solution after cataract surgery
Drug: Moxifloxacin
Intracameral injection
Other Names:
  • active
Placebo Comparator: Placebo group
Intracameral injection of placebo after cataract surgery
Drug: Placebo
intracameral injection
Other Names:
  • sham

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Endophthalmitis after cataract surgery
Time Frame: Subjects will undergo eye examinations at one day, one week, and one month post-operatively
Subjects will be followed after cataract surgery and have post-operative eye examinations to determine if infection in the eye (endophthalmitis) occurs during the study period.
Subjects will undergo eye examinations at one day, one week, and one month post-operatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jason Ahee, M.D.

Investigators

  • Principal Investigator: Jason Ahee, M.D., Zion Therapeutics, LLC

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

October 1, 2030

Study Completion (Estimated)

October 1, 2031

Study Registration Dates

First Submitted

August 4, 2017

First Submitted That Met QC Criteria

August 7, 2017

First Posted (Actual)

August 9, 2017

Study Record Updates

Last Update Posted (Estimated)

September 25, 2025

Last Update Submitted That Met QC Criteria

September 21, 2025

Last Verified

August 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • PIND 134134

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Endophthalmitis

Clinical Trials on Moxifloxacin

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe